The Vascular Endothelial Growth Factor A pipeline drugs market research report outlays comprehensive information on the Vascular Endothelial Growth Factor A targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA), and molecule type. GlobalData’s report assesses the drugs in the Vascular Endothelial Growth Factor A pipeline by therapy areas, indications, stages, MoA, RoA, molecule type and the key players in the development pipeline. Buy the report here.
The report also covers products from therapy areas such as Ophthalmology, Oncology, Genetic Disorders, and Infectious Disease which include the indications Wet (Neovascular / Exudative) Macular Degeneration, Diabetic Macular Edema, Metastatic Colorectal Cancer, Non-Small Cell Lung Cancer, Neurofibromatoses Type II, Hereditary Hemorrhagic Telangiectasia (Osler–Weber–Rendu Disease), and Recurrent Respiratory Papillomatosis (Juvenile Laryngeal Papilloma or Laryngeal Papilloma). It also reviews key players involved in Vascular Endothelial Growth Factor A targeted therapeutics development with respective active and dormant or discontinued products.
The Vascular Endothelial Growth Factor A pipeline targets constitutes close to 136 molecules. Out of which, approximately 132 molecules are developed by companies and the remaining by the universities/institutes. The molecules developed by companies in Pre-Registration, Filing rejected/ Withdrawn, Phase III, Phase II, Phase I, IND/ CTA Filed, Preclinical, and Discovery stages are 10, 4, 34, 9, 17, 4, 37, and 11 respectively. Similarly, the universities portfolio in Preclinical comprises 4 molecule.
Vascular Endothelial Growth Factor A overview
Vascular endothelial growth factor A (VEGF-A), also known as vascular permeability factor (VPF), is a signaling protein that plays a critical role in angiogenesis, the process of forming new blood vessels. It is a member of the VEGF family, which comprises several closely related proteins that share similar functions. VEGF-A is the most abundant member of the family and is considered the primary regulator of angiogenesis.
For a complete picture of Vascular Endothelial Growth Factor A’s drug pipeline, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.